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Decentralisation, integration, and task-shifting in 
hepatitis C virus infection testing and treatment: a global 
systematic review and meta-analysis
Ena Oru, Adam Trickey, Rohan Shirali, Steve Kanters, Philippa Easterbrook
Summary 
Background Increasing access to hepatitis C virus (HCV) care and treatment will require simplified service delivery 
models. We aimed to evaluate the effects of decentralisation and integration of testing, care, and treatment with 
harm-reduction and other services, and task-shifting to non-specialists on outcomes across the HCV care continuum.
Methods For this systematic review and meta-analysis, we searched PubMed, Embase, WHO Global Index Medicus, 
and conference abstracts for studies published between Jan 1, 2008, and Feb 20, 2018, that evaluated uptake of HCV 
testing, linkage to care, treatment, cure assessment, and sustained virological response at 12 weeks (SVR12) in people 
who inject drugs, people in prisons, people living with HIV, and the general population. Randomised controlled 
trials, non-randomised studies, and observational studies were eligible for inclusion. Studies with a sample size of ten 
or less for the largest denominator were excluded. Studies were categorised according to the level of decentralisation: 
full (testing and treatment at same site), partial (testing at decentralised site and referral elsewhere for treatment), or 
none. Task-shifting was categorised as treatment by specialists or non-specialists. Data on outcomes across the HCV 
care continuum (linkage to care, treatment uptake, and SVR12) were pooled using random-effects meta-analysis.
Findings Our search identified 8050 reports, of which 132 met the eligibility criteria, and an additional ten reports 
were identified from reference citations and grey literature. Therefore, the final synthesis included 142 studies from 
34 countries (20 [14%] studies from low-income and middle-income countries) and a total of 489 996 patients 
(239 446 [49%] from low-income and middle-income countries). Rates of linkage to care were higher with full 
decentralisation compared with partial or no decentralisation among people who inject drugs (full 72% [95% CI 
57–85] vs partial 53% [38–67] vs none 47% [11–84]) and among people in prisons (full 94% [79–100] vs partial 
50% [29–71]), although the CIs overlap for people who inject drugs. Similarly, treatment uptake was higher with full 
decentralisation compared with partial or no decentralisation (people who inject drugs: full 73% [65–80] vs partial 
66% [55–77] vs none 35% [23–48]; people in prisons: full 72% [48–91] vs partial 39% [17–63]), although CIs overlap for 
full versus partial decentralisation. The results in the general population studies were more heterogeneous. SVR12 
rates were high (≥90%) across different levels of decentralisation in all populations. Task-shifting of care and treatment 
to a non-specialist was associated with similar SVR12 rates to treatment delivered by specialists. There was a severe or 
critical risk of bias for 46% of studies, and heterogeneity across studies tended to be very high (I²>90%).
Interpretation Decentralisation and integration of HCV care to harm-reduction sites or primary care showed some 
evidence of improved access to testing, linkage to care, and treatment, and task-shifting of care and treatment to 
non-specialists was associated with similarly high cure rates to care delivered by specialists, across a range of 
populations and settings. These findings provide support for the adoption of decentralisation and task-shifting to 
non-specialists in national HCV programmes.
Funding Unitaid.
Copyright © 2021 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any 
specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the article’s original URL.
Introduction 
Hepatitis C virus (HCV) infection is a major cause of 
liver disease that leads to approximately 399 000 deaths 
annually.1 An estimated 71 million people are chronically 
infected, with a disproportionately high burden in 
low-income and middle-income countries (LMICs). In 
recognition of this major global public health burden, 
in 2016, WHO launched a Global Health Sector Strategy 
on Viral Hepatitis 2016–2021.2 This strategy outlined 
a set of global targets and the scale-up of five key 
synergistic interventions for prevention, testing, and 
treatment to achieve the goal of eliminating viral 
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hepatitis as a public health threat by 2030 (ie, a reduction 
in hepatitis-related mortality by 65% and in incidence of 
chronic infections by 90%). Good progress has been 
made in several key LMICs, such as Egypt, Georgia, 
Rwanda, and Mongolia, in the scale-up of treatment 
access and highly effective preventive approaches to 
reduce transmission, such as blood and injection safety.3 
However, we are far from achieving the 2030 coverage 
targets of 90% diagnosis and 80% treatment of those 
infected. As of 2017, only 20% of people with HCV 
infection had been tested and approximately a quarter 
of diagnosed people were treated.4
The global response and opportunities for elimination 
of HCV infection have been transformed by advances in 
treatment and diagnostics, as well as by price reductions.3 
These advances include the introduction of curative, 
short-course direct-acting antiviral (DAA) therapy in 
2014, and the widespread availability of rapid diagnostic 
testing for HCV antibody and availability of nucleic acid 
testing or core antigen testing for HCV viraemia. The 
development of evidence-based WHO guidelines for a 
simplified public health approach for HCV testing and 
treatment, and recommendations for a treat-all approach 
regardless of stage of disease using a few pangenotypic 
regimens, has provided further support for the scale-up 
of testing and treatment.5–7 However, until recently, data 
have been scarce and little attention has been paid to the 
optimal approaches to service delivery of HCV testing, 
care, and treatment in different settings and populations. 
Much of the evidence to inform simplified approaches, 
such as decentralisation of care to primary-care facilities 
and task-shifting to nurses and non-specialists, is based 
on the HIV literature,8 in which adoption of these 
approaches had a transformative impact on the scale-up 
of antiretroviral treatment.9 There are even greater 
opportunities with HCV infection compared with HIV, 
because care and short-course curative treatment 
requires minimal expertise and monitoring.
Although previous reviews of interventions to 
promote uptake of HCV testing and treatment have been 
done, to our knowledge none have comprehensively 
addressed the effects of decentralisation of testing and 
treatment beyond tertiary-level or specialist facilities to 
the primary-care or secondary-care level, or task-shifting 
of care to non-specialists, and previous reviews have not 
included studies from LMICs.10–17 We did a systematic 
Research in context
Evidence before this study
We searched PubMed, Embase, WHO Global Index Medicus, 
WHO International Clinical Trials Registry, and conference 
abstracts for studies of models of hepatitis C virus (HCV) care. 
The search included studies in all languages published from 
Jan 1, 2008, to Feb 20, 2018. The following search terms were 
used: “hepatitis C OR HCV” AND “delivery of health care” OR 
“delivery of health care, integrated” OR “model of care” OR 
“community care” OR “primary care”. We identified eight 
systematic reviews that had examined different interventions 
aimed to increase uptake of HCV testing, linkage to care, and 
treatment. The studies in these systematic reviews were mostly 
from high-income countries, focused only on certain steps in 
the care cascade, and were predominantly among people who 
inject drugs. Many were also done before the introduction of 
direct-acting antivirals (DAAs) and had small sample sizes 
(<50 patients). Nonetheless, previous studies found evidence 
that strategies such as offering HCV testing and care within 
harm-reduction services and primary care clinics would improve 
uptake of care and treatment.
Added value of this study
To inform future WHO global recommendations on simplified 
service delivery for HCV care and treatment, we assessed the 
effects of a range of different service delivery approaches, 
specifically decentralisation and task-shifting, on all key 
outcomes along the cascade of HCV care in people who inject 
drugs, people in prisons, people living with HIV, and the general 
population. Outcomes evaluated included uptake of serological 
and nucleic acid testing, linkage to care, treatment, cure 
assessment (ie, sustained virological response at 12 weeks after 
the end of treatment, SVR12), and cure rate. Overall, studies 
that provided fully decentralised care had similar cure rates (for 
both interferon-based and DAA-based regimens) to those 
achieved at tertiary centres, but also had increased linkage to 
care and treatment among people who inject drugs, at sites 
where HCV testing and treatment were also integrated with 
delivery of harm-reduction services. Among people in prisons, 
studies with fully decentralised care had higher rates of linkage 
to care than those with partially decentralised care. Our study 
also showed that in all populations studied, task-shifting of 
HCV care and treatment to non-specialists achieved similarly 
high SVR12 cure rates to care provided by specialists.
Implications of all the available evidence
To meet the global targets for elimination of HCV, access to 
testing and treatment needs to be scaled up substantially. Our 
findings provide new evidence that decentralisation of testing, 
care, and treatment to harm-reduction sites among people who 
inject drugs and within prisons improves linkage to care and 
treatment, as well as achieving high cure rates. We also found 
that care delivered by non-specialists has similar outcomes to 
that delivered by specialists. This finding has direct implications 
for countries where HCV care and treatment are currently 
restricted to certain tertiary-care facilities or provided only by 
specialists (eg, hepatologists). Our results provide support for 
countries to expand access to their services for HCV testing, 
care, and treatment beyond specialist centres and providers to 
lower-level health facilities and to use the existing 
non-specialist and primary health-care workforce.
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review and meta-analysis of published literature, grey 
literature, and unpublished sources to synthesise 
evidence on the effectiveness of these service delivery 
approaches. The specific interventions considered were 
full decentralisation of testing and treatment at the same 
site or partial decentralisation of testing but referral 
elsewhere for treatment, integration of HCV testing and 
treatment with harm-reduction and other services, and 
task-shifting of care and treatment to non-specialists. We 
evaluated the effects of these interventions on six key 
outcomes across the HCV care cascade: uptake of 
serological testing, uptake of viral load testing, linkage to 
care, treatment uptake, uptake of cure assessment, and 
attainment of treatment cure. These outcomes were 
evaluated in four populations most affected by HCV 
infection: people who inject drugs, people in prisons, and 
people living with HIV, as well as the general population.
Methods 
Search strategy and selection criteria 
We did a systematic review and meta-analysis in 
accordance with PRISMA guidelines. We did a 
comprehensive search of PubMed, Embase, and WHO 
Global Index Medicus for studies reporting models of 
HCV care. The search was done on Feb 20, 2018, and 
included studies in all languages published from 
Jan 1, 2008. A further updated search was done on 
April 1, 2020, to identify studies published from 
Feb 21, 2018, to Feb 28, 2020. Searches were tailored to 
the functionality of each database, but generally used the 
following terms: “hepatitis C OR HCV” AND “delivery of 
health care” OR “delivery of health care, integrated” OR 
“model of care” OR “community care” OR “primary 
care”. In addition, accepted conference abstracts from 
the World Hepatitis Summit (2017), the International 
Network on Hepatitis in Substance Users (2015–18), the 
European Association for the Study of the Liver (2015–18), 
the American Association for the Study of Liver Diseases 
(2015–18), and the Asian Pacific Association for the Study 
of the Liver (2015–18) were searched. The reference lists 
of all retrieved articles, as well as review articles identified 
during the initial search, were screened for relevant 
citations. Forward citation checks were done to identify 
any additional studies. Full details of the search strategy 
are provided in the appendix (p 1). A secondary search on 
Google search engine and the WHO International 
Clinical Trials Registry was done to identify existing grey 
literature (appendix p 1). The contacts directory of the 
WHO Global Hepatitis Programme was also used to 
solicit additional studies of hepatitis service delivery 
from LMICs.
Authors EO and AT did the search and independently 
evaluated retrieved articles, abstracts, and grey literature 
to determine the eligibility of the study according to 
the inclusion criteria. PE reviewed final selection and 
arbitrated when there were differences between the 
two primary reviewers. Citations generated by electronic 
scanning were assessed for relevance based on title, 
abstracts, and descriptor terms. We included randomised 
controlled trials (RCTs), non-randomised studies, and 
observa tional studies that reported interventions along 
the early phase of the care continuum, including 
serological testing, confirmatory viral load testing, and 
linkage to care, and the late phase of the care continuum, 
including treatment uptake, assessment of cure 
(sustained virological response at 12 weeks after 
completion of treatment [SVR12]), and cure rate (SVR12) 
for chronic HCV infection in adults (≥18 years). If 
necessary, data obtained from abstracts or grey literature 
were returned to authors for verification or provision of 
additional information. Studies with a sample size of ten 
or less for the largest denominator were excluded.
Data analysis 
Data were extracted from eligible studies and entered into 
preformatted spreadsheets. The following data points 
were extracted: study design, participant population, 
See Online for appendix
Figure 1: Study selection
AASLD=American Association for the Study of Liver Diseases. APASL=Asian Pacific 
Association for the Study of the Liver. EASL=European Association for the Study of 
the Liver. INHSU=International Network on Hepatitis in Substance Users.
695 reports identified by search of 
conference abstracts
 268 INHSU






7355 reports identified by database 
search
 2806 PubMed or MEDLINE 
 2833 Embase
 585 WHO Global Index 
Medicus 
 1131 WHO International 
Clinical Trials Registry
 
5283 studies excluded based on 
abstract   
173 studies reviewed and  
assessed for eligibility 
41 studies excluded
 26 no description of model 
of care
 2 review articles
 10 no quantitative
outcomes
 2 duplicate studies
 1 sample size too small
10 additional studies identified
 5 identified by reference 
citations
 5 identified by grey literature 
and contacts list
142 studies included in 
quantitative synthesis 
 75 full-text articles 
 64 conference abstracts 
 3 project reports
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location or setting of testing and treatment, the role of the 
health providers, and the scope of care provided. If testing 
was reported, additional interventions used to promote 
testing uptake, access to confirmatory viral load testing, 
and linkage to care were recorded. If treatment was 
reported, we documented methods of staging of liver 
disease, and treatment regimens used. For consistency, 
testing uptake was recorded as the proportion of 
participants tested relative to all those offered testing, 
whereas treatment uptake was based only on participants 
who had undergone viral load testing, initial staging, 
and treatment assessment. If a single study contained 
comparator groups, data from both groups were recorded 
in the relevant intervention category (eg, full, partial, or 
no decentralisation). The main outcomes of interest were 
HCV serological and viral load testing, linkage to care, 
treatment, cure assessment, and SVR12.
Studies were classified according to levels of decen-
tralisation for testing and treatment. Full decentralisation 
was defined as when both testing and treatment occurred 
at a primary health clinic or district hospital, harm-
reduction site, or prison; partial decentralisation was 
defined as when testing occurred at a primary level 
facility followed by referral elsewhere for treatment; and 
no decentralisation was defined as when testing and 
treatment occurred at tertiary or specialist sites only. For 
studies of people who inject drugs, people in prisons, 
and people living with HIV, integration was defined as 
when HCV testing and treatment were done at harm-
reduction sites, in prisons, or at HIV clinics alongside 
delivery of other key harm-reduction interventions, such 
as opiate substitution therapy (OST) or a needle-syringe 
exchange programme (NSP), or HIV care. Task-shifting 
was defined as delivery of HCV care and treatment 
by non-specialist physicians or nurses rather than 
specialists (eg, hepatologists). Among people who inject 
drugs, we categorised care facilities into three main 
groups: traditional OST facilities (often referred to 
as methadone maintenance therapy programmes or 
medication-assisted therapy programmes); NSP facilities 
Total 
(142 studies)










Low-income and middle-income countries 20 (14%) 7 (9%) 10 (27%) 1 (5%) 2 (40%)
Coverage of outcomes in care cascade
Early phase of cascade (testing with or without linkage) 17 (12%) 8 (10%) 2 (5%) 7 (35%) 0
Late phase of cascade (treatment with or without 
linkage)
87 (61%) 53 (66%) 24 (65%) 8 (40%) 2 (40%)
Full cascade 38 (27%) 19 (24%) 11 (30%) 5 (25%) 3 (60%)
Decentralisation*
Number of decentralisation study groups 154 86 41 20 7
Full decentralisation (and integration)† 88 (57%) 55 (63%) 16 (39%) 12 (60%) 5 (71%)
Partial decentralisation (testing at site, referral for care) 44 (29%) 25 (29%) 11 (27%) 8 (40%) 0
No decentralisation 22 (14%) 6 (7%) 14 (34%) 0 2 (29%)
Task-shifting*
Number of task-shifting study groups 153 82 44 20 6
Non-specialist treatment 46 (30%) 27 (33%) 10 (23%) 6 (30%) 3 (50%)
Non-specialist treatment with onsite or telehealth-
guided specialist support
24 (16%) 15 (18%) 4 (9%) 4 (20%) 1 (17%)
Specialist treatment 51 (33%) 20 (24%) 25 (57%) 3 (15%) 2 (33%)
Unknown or not applicable 32 (21%) 20 (24%) 5 (11%) 7 (35%) 0
Treatment regimen
DAAs 83 (58%) 50 (63%) 19 (51%) 10 (50%) 4 (80%)
DAAs with interferon-based regimen 7 (5%) 4 (5%) 3 (8%) 0 0
Interferon-based regimen 35 (25%) 18 (23%) 13 (35%) 3 (15%) 1 (20%)
Not applicable 17 (12%) 8 (10%) 2 (5%) 7 (35%) 0
Study design
Randomised controlled trial 6 (4%) 6 (8%) 0 0 0
Non-randomised trials 2 (1%) 1 (1%) 1 (3%) 0 0
Comparative prospective or retrospective study 11 (8%) 2 (3%) 6 (16%) 1 (5%) 2 (40%)
Non-comparative observational study 123 (87%) 71 (89%) 30 (81%) 19 (95%) 3 (60%)
Data are number of study groups, number of studies (%) or number of study groups (%). One study was stratified by people who inject drugs and people in prison, so it was 
included in this table twice. DAA=direct-acting antiviral. *Studies that had comparator groups with different levels of decentralisation or task-shifting were included in 
multiple categories. †Includes ten studies that use an embedded specialist clinic with care provided by visiting specialists.
Table 1: Summary of characteristics of 142 included studies
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(including drop-in centres and safe injection facilities); 
and primary-care clinics.
Authors EO and AT assessed the risk of bias for RCTs, 
non-randomised studies, and observational studies using 
the modified Downs and Black criteria.18 Outcomes were 
assessed for reporting bias, selection bias, internal validity 
bias, and external validity bias. For study quality, the 
STROBE guidelines for reporting of observational studies 
and conference abstracts were used.19 
When interventions were sufficiently similar across 
different studies, binomial outcomes for effect sizes were 
pooled and summarised with 95% CIs, adjusted using 
the Wald method.20 Summary statistics, illustrated as 
forest plots for outcomes of interest, were calculated 
using meta-analytic methods stratified by population 
type, using the Freeman-Tukey correction method, and 
with random-effects models using the DerSimonian and 
Laird approach (fixed-effect models were used if 
heterogeneity was <20%).21 Heterogeneity was assessed 
using the I² statistic,21 and publication bias assessed 
using Begg’s test.22 Meta-regression was used to assess 
the effect of decentralisation on double arcsin-
transformed outcome measures, as well as the effects of 
selected independent variables.23 We also pooled results 
from the subset of studies with a comparator group, 
including both randomised trials and non-randomised 
studies, and compared these with results from pooled 
analysis of non-comparator studies. p values obtained for 
comparative studies were from pairwise meta-analyses, 
whereas a two-sample z-test was used for non-comparative 
studies. Additional analyses were done to examine the 
effect of different types of harm-reduction service (NSP, 
OST, and other) on outcomes in studies of people who 
inject drugs; and the effect of the specific service provider 
(nurse, general practitioner [primary-care doctor], or 
specialist) on SVR12 in studies of task-shifting. Analyses 
were done using R version 3.6.1 and Stata version 15.1.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Our search identified 8050 reports, of which 
5456 remained after removing duplicates (figure 1). After 
screening of abstracts, 5283 studies were excluded. The 
remaining 173 studies were reviewed and assessed for 
eligibility, of which 41 did not meet the eligibility criteria 
and were excluded. An additional ten studies were 
identified from reference citations and grey literature. 
142 studies were included in the final synthesis, including 
one report with data on both people in prisons and people 
who inject drugs, which was counted as two separate 
studies. These studies included a total of 489 996 patients 
(239 446 [49%] from LMICs). Two additional papers 
identi fied by the updated search were not included 
because they did not provide any information that would 
have contradicted our findings on decentrali sation, 
integration, and task-shifting.
Study characteristics are summarised in table 1 and the 
appendix (pp 2–25). 80 (56%) of 142 studies were focused 
on people who inject drugs, 20 (14%) on people in prisons, 
five (4%) on people living with HIV, and 37 (26%) on 
the general population. Figure 2 shows the geographical 
distribution of the included studies, of which 123 (87%) 
were from high-income countries, with the largest 
numbers from the USA (41 studies, 29%), Australia 
Figure 2: Geographical distribution of the 142 included studies
Countries in which studies were done are shaded red.
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Seidenburg et al (2013)
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Hashim et al (2018)
Olaizola et al (2018)
O'Loan et al (2018)
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Residual heterogeneity: I2=98%, p<0·0001
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(27, 19%), the UK (18, 13%), and Canada (17, 12%). 
20 (14%) studies were from LMICs, and included seven 
studies in people who inject drugs (Turkey, India, China, 
Kenya, Georgia, Romania, and Iran), one study in people 
in prisons (Ukraine), two studies in people living 
with HIV (Myanmar and Mozambique), and ten studies 
in the general population (Pakistan, Egypt, Indonesia, 
Cameroon, Cambodia, China, and two studies each in 
India and Brazil). In the 37 studies in the general 
population (across all income settings), care was provided 
in primary-care settings in ten studies and in hospital-
based clinics in 27 studies. Most studies in people who 
inject drugs were based at harm-reduction sites offering 
OST (48 studies), with another 14 studies in NSPs and 
18 studies in other locations, such as clinics for homeless 
people or drop-in centres.
39 (27%) studies had a low risk of bias (score ≥20), 
38 (27%) studies had a moderate risk (score 15–19), 
49 (35%) studies had a serious risk of bias (score 10–14), 
and 16 (11%) had a critically high risk of bias (score <10; 
appendix p 26). The overall risk of bias was rated as 
moderate. Among analyses with at least ten studies, 
evidence of publication bias was only found for higher 
SVR12 rate among interferon-based regimen studies 
(p=0·012; appendix p 27).
In studies using DAAs, outcomes across the care cascade 
(linkage to care, treatment uptake, and SVR12) according 
to different levels of decentralisation among people who 
inject drugs, people in prisons, and the general population 
are presented in figure 3, figure 4, and the appendix 
(pp 28–40; data for studies using interferon-based 
regimens are presented in the appendix pp 28–38). 
Heterogeneity across studies in each analysis (grouped 
either by decentrali sation or task-shifting) was generally 
very high. Heterogeneity of outcomes was particularly 
high for serological testing uptake (I²>95%), and therefore 
we did not report further on this outcome in the main 
results, and also for treatment uptake and SVR12 for 
interferon-based regimens. There were insufficient studies 
among people living with HIV for a robust examination 
of outcomes according to levels of decentralisation 
(appendix pp 41–42). Coefficients (and 95% CIs) of meta-
regressions analysing differences according to levels of 
decentralisation for each outcome by population group are 
provided in the appendix (pp 49–51; analyses according to 
the presence or absence of task-shifting are on p 52).
Among people who inject drugs, full decentralisation 
of HCV testing and treatment (and when also integrated 
with delivery of harm reduction services [OST, NSP, or 
both]) showed some evidence of being associated with 
both increased linkage to care (full decentralisation 
72% of patients linked to care [95% CI 57–85] vs partial 
decentralisation 53% [38–67] vs no decentralisation 
47% [11–84]; figure 3A) and increased DAA treatment 
uptake (full decentralisation 73% [65–80] vs partial 
decentralisation 66% [55–77] vs no decentralisation 
35% [23–48]; figure 4A), although with overlapping CIs. 
Based on an examination of both the estimates and CIs 
from the meta-analyses and the meta-regression analyses 
(appendix p 51), the evidence was strongest for higher 
levels of treatment uptake with full decentralisation 
versus none. There was increased nucleic acid testing 
Figure 3: Effect of decentralisation and integration on linkage to care for people who inject drugs, people in prisons, and the general population
Study details are provided in the appendix (pp 2–25). RCT=randomised controlled trial. MDT=multidisciplinary team. 
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uptake and linkage to care with full decentralisation 
versus partial or none, at harm-reduction sites providing 
OST or NSP, but this was statistically significant only at 
OST sites (appendix p 48).
Among people in prisons, there was also some evidence 
of increased linkage to care (full decentralisation 94% of 
patients linked to care [95% CI 79–100] vs partial 
50% [29–71]; figure 3B) and increased treatment uptake 
(full decentralisation 72% of patients started DAA 
treatment [48–91] vs partial 39% [17–63]; figure 4B) with 
fully decentralised testing and treatment at the same site 
within a prison, compared with partial decentralisation, 
in which individuals were referred elsewhere for 
treatment after testing, although with overlapping CIs. 
Based on an examination of both the estimates and CIs 
from the meta-analyses and the meta-regression analyses 
(appendix p 51), there was strong evidence for increased 
linkage to care with full versus partial decentralisation 
among people in prisons.
Among the general population, the outcomes were 
heterogeneous, with little evidence of differences in 
linkage to care or DAA treatment uptake according to 
level of decentrali sation (figures 3C, 4C). Similarly, in the 
meta-regression analyses (appendix p 51), we found no 
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Norton et al (2017)
Morris et al (2018)
Olaizola et al (2018)
Page et al (2018)
Bourke et al (2018)
von Bibra et al (2018)
Bieser et al (2018)
Radley et al (2018), intervention group
Hashim et al (2018)
Ho et al (2013)
Traeger et al (2018)
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Residual heterogeneity: I2=95%, p<0·0001
(Figure 4 continues on next page)
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With use of DAA-based regimens, similar high SVR12 
rates (≥90%) were achieved regardless of level of 
decentralisation for people who inject drugs (full 
decentralisation 95% [95% CI 93–97] vs partial 91% 
[86–95] vs none 94% [91–97]; appendix p 39), people in 
prisons (full 98% [96–99] vs partial 100% [77–100]; 
appendix p 40), people living with HIV (full 95% [87–99] 
vs none 100% [96–100]; appendix p 41), and the general 
population (full 93% [90–96] vs partial 94% [88–98] vs 
none 96% [92–99]; appendix p 40). In the meta-
regression analyses (appendix p 52), we found no 
differences in DAA SVR12 rates according to level of 
decentralisation.
Task-shifting of care and treatment to a non-specialist 
was associated with similar SVR12 rates to treatment 
delivered by specialists using DAA-based regimens 
(appendix pp 43–45) in people who inject drugs (non-
specialist 96% [95% CI 93–98] vs specialist 92% [88–96]), 
people in prisons (non-specialist 98% [96–99] vs specialist 
100% [77–100]), people living with HIV (non-specialist 
98% [96–99] vs specialist 100% [96–100]), and the general 
population (non-specialist 94% [90–97] vs specialist 
94% [92–96]). Similarly, task-shifting of care and 
treatment was associated with similar SVR12 rates using 
interferon-based regimens (appendix pp 45–47). The 
meta-regressions for both interferon-based and DAA 
regimens showed no evidence of differences between 
specialist-led and non-specialist-led treatment (appendix 
p 52). The number of studies was insufficient to 
investigate differences between specialist and non-
specialist treatment providers  among people living with 
HIV and people in prisons.
Figure 4: Effect of decentralisation and integration on direct-acting antiviral treatment uptake for people who inject drugs, people in prisons, and the general 
population


























































































0·2 0·4 0·6 0·8 1·0
0·2 0·4 0·6 0·8 1·0
Total Proportion (95% CI) WeightEvents
B





Cuadrado et al (2018)
Fridriksdottir et al (2018)
Morey et al (2018)
Bachelard et al (2018)









Residual heterogeneity: I2=94%, p<0·0001
Full decentralisation
Cooper et al (2017), intervention group (RS)
Belperio et al (2017)
Mera et al (2016)
Ford et al (2018)




Shiha et al (2018)
Anartati et al (2018)
Smyth et al (2017)
Falade Nwulia et al (2016)









Residual heterogeneity: I2=99%, p<0·0001
Articles
e440 www.thelancet.com/lancetgh   Vol 9   April 2021
Of 142 studies, 13 (9%) had comparator groups (RCTs, 
non-randomised trials, or prospective cohort studies) and 
had examined the effect of decentralisation of care or 
task-shifting of care and treatment to non-specialists. A 
comparison of available outcomes from this subgroup of 
studies using DAA regimens across groups with different 
levels of decentralisation (seven studies) and task-shifting 
(five studies), with the corresponding results for the 
non-comparative studies, are shown in tables 2, 3, and 4 
(outcomes of studies using interferon-based regimens 
are shown in the appendix pp 53–56). Findings were 
generally consistent between comparative and non-
comparative studies. Among people who inject drugs, 
linkage to care and treatment uptake were considerably 
higher with full decentralisation compared with no 
decentralisation, with smaller increases observed for 
full decentralisation versus partial decentralisation 
(table 2). For SVR12, there were no differences by level of 
decentralisation or task-shifting status for any population 
(tables 3, 4). Meta-analyses of studies with comparator 
groups also showed similar results for full decentralisation 
versus partial or no decentralisation across all outcomes 
to those observed from the overall meta-analysis. Meta-
regression analyses for outcomes according to level of 
decentralisation and population were limited by the 
lack of comparative studies, with only one study available 
for many of the comparisons (appendix pp 53–56). 
Results of the meta-regression analyses of study variables 
on the outcomes are presented and described in the 
appendix (p 49).
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Number of studies 12 15 ·· ·· 21 10 ·· ·· 28 4 ·· ··
General population
Full vs partial decentralisation



























Number of studies ·· ·· ·· ·· 4 4 ·· ·· 10 4 ·· ··
A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise meta-analyses of dichotomous outcomes. p values for non-comparative studies were from 
two-sample z-tests comparing the results of meta-analyses for proportions using double arcsin transformations. RCT=randomised controlled trial. RCS=retrospective comparative study. PCS=prospective 
comparative study.
Table 2: Comparison of linkage to care, treatment uptake, and cure assessment in direct-acting antiviral regimen studies with or without comparative groups, according to population 
group and level of decentralisation
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In addition to levels of decentralisation and task-shifting, 
other interventions were used in the various studies to 
promote uptake of testing. However, the use of multiple 
combinations of different strategies and outcomes pre-
cluded a formal quantitative analysis of their independent 
contribution, or attribution of an outcome to a particular 
intervention. We identified 11 (8%) studies that achieved 
high levels of coverage (>75%) for at least three steps 
across the care cascade (testing uptake, nucleic acid 
testing uptake, linkage to care, treatment uptake, and 
cure assessment).24–32 These studies included two in the 
general population;24,25 one in people in prisons (full 
decentralisation);26 two in people living with HIV (Nguyen 
A, Médecins Sans Frontières, personal com munication); 
and six in people who inject drugs (full decentralisation27–31 
and partial decentralisation32). Across these studies, 
common strategies were adopted that have previously 
been shown to promote testing (use of rapid diagnostic 
tests, laboratory-based enzyme immuno assay,28,29,32 villager 
or peer workers,24 and use of dried blood spot testing32); 
uptake of nucleic acid testing (reflex laboratory nucleic 
acid testing,27,28 immediate sample collection following 
positive rapid diagnostic test,24,25 or use of point-of-care 
viral load assays); linkage to care (use of village promoters 
or peer workers and provision of sample transport);24 and 
treatment uptake (free treatment,24 peer workers,24 and 
non-specialists25,27,29,31).
Discussion 
To our knowledge, this global systematic review is the 
most comprehensive review of service delivery models 
for HCV care to date. It was based on 142 studies from 
34 countries, of which around a sixth were LMICs. It 
encompassed studies in four main affected populations: 
people who inject drugs, people in prisons, people living 
with HIV, and the general population, and examined 
the effects of different levels of decentralisation and 
task-shifting on all six key outcomes across the cascade 
of care.
This study has three key findings. First, we found that 
full decentralisation and integration of HCV testing and 
treatment at sites providing harm-reduction services 
(OST, NSP, or both, and also mental health support) 
for people who inject drugs and on site for people 
in prisons was associated with increased linkage to 
care and treatment. The strongest evidence was for 
improved treatment uptake with full decentralisation 
and integrated care among people who inject drugs, 
and for linkage to care with full decentralisation and 
integrated care among people in prisons. Second, 
similarly high rates of HCV cure (SVR12) were found in 
a wide range of decentralised settings for care and 
treatment, including harm-reduction sites, prisons, and 
primary-care or community settings, to those found 
when care was delivered in tertiary-level facilities. Third, 
task-shifting to non-specialist primary-care physicians 
or nurses was associated with similarly high levels of 
HCV cure using DAA regimens to those achieved by 
specialist-delivered care in all populations studied. 
Similar findings were also observed in studies using the 
older interferon-based regimens, as opposed to DAA 
regimens.
Our findings are consistent with those from the HIV 
literature, which show similar rates of viral suppression 
on antiretroviral therapy (ART), as well as increased 
uptake of testing and treatment, with full decentralisation 
(ie, community-based HIV testing and treatment at 
lower-level health facilities) compared with no decentral-
isation15,33–35 and also with care delivered by non-specialists, 
including nurses, compared with care delivered by 
specialists.36–38 In our study, the effects of decentralisation 










People who inject drugs
Full decentralisation vs none
Comparative 100% (78–100) ·· 100% (72–100) 0·688
Wade et al (2018), RCT 100% (78–100) ·· 100% (72–100) ··
Middleton et al (2018), 
RCS
·· ·· ·· ··
Non-comparative 95% (93–97) ·· 94% (90–97) 0·627
Number of studies 28 ·· 3 ··
Full vs partial decentralisation
Comparative 91% (84–95) 93% (90–95) ·· 0·422
Radley et al (2018), RCT ·· ·· ·· ··
Alavi et al (2018), PCS ·· ·· ·· ··
Cooper et al (2017), RCS ·· ·· ·· ··
McClure et al (2017), PCS Nurse 88% (78–95); 
GP 93% (82–99)
93% (90–95) ·· ··
Non-comparative 95% (93–97) 90% (83–96) ·· 0·150
Number of studies 28 6 ·· ··
General population
Full vs partial decentralisation
Comparative 95% (74–100) 95% (91–97) ·· 0·780
Cooper et al (2017), RCS 95% (74–100) 95% (91–97) ·· ··
Non-comparative 93% (90–96) 93% (86–98) ·· 1·000
Number of studies 10 4 ·· ··
People living with HIV
Full decentralisation vs none
Comparative 94% (88–99) ·· 100% (93–100) 0·867
Doyle et al (2018), NRS 94% (88–99) ·· 100% (93–100) ··
Non-comparative 99% (97–100) ·· NA NA
Number of studies 3 ·· 0 ··
A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise 
meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests 
comparing the results of meta-analyses for proportions using double arcsin transformations. SVR12=sustained 
virological response at 12 weeks after completion of treatment. GP=general practitioner. RCT=randomised controlled 
trial. RCS=retrospective comparative study. PCS=prospective comparative study. NRS=non-randomised study. NA=not 
applicable (tests could not be performed due to a paucity of data).
Table 3: Comparison of SVR12 outcomes in direct-acting antiviral regimen studies with or without 
comparative groups, according to population group and level of decentralisation
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those in prisons. People who inject drugs, in particular, 
have difficulties accessing health services, including 
getting tested, linking to care, and navigating tertiary-care 
services.39 Similar to our systematic review, previous 
studies of ART have shown positive effects of the 
provision of integrated HIV care for people who inject 
drugs, with on-site community HIV testing and ART 
treatment.40–42 For HIV, the convenient co-location of 
testing and treatment integrated within OST services or 
primary care or community sites, where multiple needs 
can be met in one accessible setting, has been an 
important facilitator of access to care for people who 
inject drugs.8,41–43 WHO currently recommends offering 
HIV care and ART at OST sites.8,42 Our study findings 
regarding HCV support similar integration of HCV 
testing and treatment, and also provide new evidence that 
integration and co-location of HCV care and treatment 
can be effective not only at OST sites, but also at NSP 
sites.
There was considerable heterogeneity in outcomes 
(especially for testing uptake) across populations, 
care settings, treatment regimen, and service delivery 
interventions. However, SVR12 results for DAAs were 
consistently high (>90%) across all populations, care 
settings (eg, OST or NSP sites, prisons, primary-care 
clinics), and types of care provider (eg, nurses, general 
practitioners, addiction specialists, hepatologists), as well 
as across different levels of decentralised and integrated 
care. These findings are consistent with reports of 
successful treatment outcomes among people who inject 
drugs, including those with recent drug use and those 
receiving OST.44 We found the strongest evidence for 
full decentralisation was among people who inject 
drugs and people in prisons, but differences by level of 
decentralisation to primary care were not observed 
among studies in the general population, for which 
results were highly heterogeneous. This discrepancy is 
probably due to the currently more well established 
models for delivery of HCV care in OST and NSP sites in 
high-income countries as compared with the diverse care 
models for delivery of HCV care in primary-care settings 
for the general population.
Key strengths of this systematic review were the large 
number of studies included, of which around a sixth 
were from LMICs, and the inclusion of additional studies 
through searches of conference presentations and grey 
literature. Our updated search from 2018 to 2020 yielded 
only two potentially eligible studies that were not 
included. We also did a comprehensive analysis of the 
effects of interventions across all six outcomes along 
the cascade of HCV care. The inclusion of single-arm 
observational studies alongside comparative studies 
considerably expanded the evidence base from LMICs, 
and it also enabled an additional comparison of findings 
between studies with comparator groups and non-
comparative studies. A high proportion of our studies 
were based on DAAs, reflecting current treatment 
practice.
There were several limitations to this systematic review. 
First, the meta-analysis was based largely on single-
arm observational studies. Few studies (13, 9%) had a 
comparator group enabling a direct comparison of 
different levels of decentralisation or task-shifting, and of 
these only four were RCTs (there were six RCTs in total). 
This may introduce considerable selection bias and result 
in an overestimate of the effects of the interventions. 
Second, studies from LMICs were still under-represented, 
and there was a relative paucity of data on the early testing 
and linkage part of the cascade compared with the later 
treatment steps in the cascade. In addition, the use of 
terminology such as decentralisation, decentralised care, 
or task-shifting is still infrequent in the HCV literature, 
and it is possible that, as a result, some relevant studies 
were overlooked in our search strategy. Third, many 
included studies used several interventions targeting 
different steps in the care cascade, such as strategies to 
promote uptake and rate of serological testing (eg, opt-out 
testing, peer and outreach workers, electronic medical 
record and clinician reminders, and rapid diagnostic 
tests), HCV RNA confirmation (eg, reflex laboratory 
testing, immediate sample collection, or point-of-care 
viral load instruments such as GeneXpert), and linkage to 
care (eg, use of peer workers or patient navigators). Of 
note, ten studies that reported consistently high levels of 
coverage (>75%) across the care cascade had, in addition 
Non-specialist care, % (95% CI) Specialist care, % 
(95% CI)
p value
People who inject drugs
Comparative 93% (86–98) 95% (92–97) 0·460
Wade et al (2018), RCT PCPs or nurses 100% (76–100) 100% (74–100) ··
McClure et al (2017), PCS Nurses 88% (78–95); GPs 93% (82–99) 93% (90–95) ··
Non-comparative 96% (94–98) 92% (86–96) 0·145
Number of studies 22 8 ··
General population
Comparative 95% (92–98) 94% (91–96) 0·466
Cooper et al (2017), RCS Nurses 95% (74–100) 95% (91–97) ··
Kattakuzhy et al (2017), NRS PCPs 95% (90–98); nurses 95% (90–98) 92% (89–95) ··
Non-comparative 93% (87–97) 94% (91–97) 0·737
Number of studies 5 9 ··
People living with HIV
Comparative 94% (88–98) 100% (93–100) 0·065
Doyle et al (2018), NRS Nurses 94% (88–98) 100% (93–100) ··
Non-comparative 99% (97–100) NA NA
Number of studies 3 0 ··
A full list of studies is provided in the appendix (pp 2–25). p values for comparative studies were from pairwise 
meta-analyses of dichotomous outcomes. p values for non-comparative studies were from two-sample z-tests 
comparing the results of meta-analyses for proportions using double arcsin transformations. SVR12=sustained 
virological response at 12 weeks after completion of treatment. RCT=randomised controlled trial. PCP=primary care 
physician. PCS=prospective comparative study. GP=general practitioner. RCS=retrospective comparative study. 
NRS=non-randomised study. NA=not applicable (tests could not be performed due to a paucity of data).
Table 4: Comparison of SVR12 outcomes in direct-acting antiviral regimen studies with or without 
comparative groups, according to population group and task-shifting status
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to full decentralisation, adopted several other well 
established interventions to promote access to testing and 
treatment. The use of multiple combinations of different 
strategies and outcomes precluded a formal quantitative 
analysis of their independent contributions, and we were 
unable to attribute an outcome to a particular interven-
tion. Fourth, financial or socioeconomic factors were not 
reported that might have adversely affected engagement 
and impact on specific outcomes such as linkage rate and 
treatment uptake, especially in people who inject drugs or 
people in prisons, as well as people who are homeless.
This systematic review highlights the need for more 
methodologically rigorous comparative studies on 
packages of different interventions to promote the uptake 
of HCV testing, and linkage to assessment and treatment 
uptake, especially in LMICs. We identified few studies of 
different models of fully decentralised HCV testing, care, 
and treatment among the general population in primary 
care, but evidence from ongoing studies is likely to be 
available over the next 2 years, when an updated review 
would be helpful. Future studies should provide a full 
description of the service delivery model, and evaluation 
should capture effectiveness of interventions across the 
entire continuum of care and not just the treatment-
related outcomes. Including costs would allow for 
comparative cost-effectiveness analyses. Additional and 
new strategies to promote testing and treatment access 
in LMICs that are currently being evaluated include the 
strategic use of point-of-care multi-platform technologies 
for measurement of HCV viral load such as GeneXpert, 
electronic medical record prompts,45,46 use of mobile 
outreach services, especially in homeless populations,47–49 
pharmacy-led testing and treatment initiation,50,51 and 
telementoring to support non-specialists.52,53
This systematic review has several major policy and 
clinical management implications for the scale-up of 
testing and treatment that is needed to achieve global 
HCV elimination targets. The WHO 2017 testing 
guidelines already recommend the adoption of several 
strategies to enhance uptake of hepatitis testing and 
linkage to care, including peer workers, clinician 
reminders for testing, and provision of testing as part of 
integrated services, based on a 2016 systematic review.5,17 
Similarly, the WHO 2018 guidelines for HCV infection 
promoted eight good-practice principles for simplified 
service delivery, including decentralisation, integration, 
and task-shifting.7 Our systematic review now provides a 
robust evidence base to support global policy and national 
guidelines for expanding HCV services beyond tertiary 
or specialist facilities to fully decentralised, co-located 
HCV testing and treatment at the primary-care and 
secondary-care level, harm-reduction services, prisons, 
and HIV clinics. We also show evidence for the 
effectiveness of task-shifting of HCV care and treatment 
to primary-care physicians and nurses, which should 
be supported by training and mentorship.6 Compared 
with HIV, there are even greater opportunities for 
decentralisation and task-shifting of HCV care and 
treatment because of the simplicity of short-course, 
curative, pangenotypic DAA regimens with minimal 
side-effects. A 2018 systematic review showed favourable 
SVR12 cure rates among people receiving OST and those 
with recent drug use.54 Of note, our study shows the 
feasibility of improving access to diagnosis and treatment 
among people who inject drugs and people in prisons, 
who are some of the most difficult populations to reach, 
which is critical to achieve elimination targets and reduce 
prevalence and ongoing transmission of HCV.
Contributors
PE conceived the study proposal, developed the overall methods and 
approach for the systematic review and meta-analysis, and oversaw the 
project. EO did the literature search. EO and AT extracted data. EO and 
AT independently assessed the quality of each record using a quality 
assessment tool. AT, RS, and SK did the analyses and generated all forest 
plots, which were reviewed by EO and PE. EO and PE led the writing of 
the manuscript, and PE with AT made all subsequent revisions to the 
manuscript. All authors commented and contributed text, and approved 
the final manuscript. EO and PE had full access to all the data in the 
study and had the final responsibility for the decision to submit for 
publication.
Declaration of interests
We declare no competing interests.
Data sharing
The full search strategy and results used to generate data that inform the 
conclusion of this systematic review can be found in the appendix.
Acknowledgments
This project was funded through an enabler grant to the WHO Global 
Hepatitis Programme from Unitaid. WHO experts were involved in the 
technical and scientific discussions of this project. The writing of this 
paper was done solely by the authors. The authors are grateful to a 
number of individuals who provided valuable input to the project and on 
the manuscript, including Marc Bulterys, Niklas Luhmann, 
Christian Ramers, Nathan Ford, and Annette Verster.
Editorial note: the Lancet Group takes a neutral position with respect to 
territorial claims in published maps and institutional affiliations.
References
1 WHO. Global hepatitis report, 2017. April, 2017. https://www.who.
int/hepatitis/publications/global-hepatitis-report2017/en (accessed 
Jan 11, 2021).
2 WHO. Global health sector strategy on viral hepatitis 2016–2021. 
June, 2016. http://www.who.int/hepatitis/strategy2016-2021/ghss-
hep/en (accessed Jan 11, 2021).
3 WHO. Global report on access to hepatitis C treatment: focus on 
overcoming barriers. October, 2016. https://apps.who.int/iris/
handle/10665/250625 (accessed Jan 11, 2021).
4 WHO. Progress report on HIV, viral hepatitis and sexually 
transmitted infections 2019. July, 2019. https://www.who.int/hiv/
strategy2016-2021/progress-report-2019/en (accessed Jan 11, 2021).
5 Easterbrook PJ, WHO Guidelines Development Group. Who to test 
and how to test for chronic hepatitis C infection—2016 WHO 
testing guidance for low- and middle-income countries. J Hepatol 
2016; 65 (suppl): S46–66.
6 WHO. Guidelines on hepatitis B and C testing. February, 2017. 
https://www.who.int/hepatitis/publications/guidelines-hepatitis-c-
b-testing/en (accessed Jan 11, 2021).
7 WHO. Guidelines for the care and treatment of persons diagnosed 
with chronic hepatitis C virus infection. July, 2018. https://www.
who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en 
(accessed Jan 11, 2021).
8 WHO. Consolidated guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection: recommendations for a 
public health approach—second edition. June, 2016. https://www.
who.int/hiv/pub/arv/arv-2016/en (accessed Jan 11, 2021).
Articles
e444 www.thelancet.com/lancetgh   Vol 9   April 2021
9 Bemelmans M, van den Akker T, Ford N, et al. Providing universal 
access to antiretroviral therapy in Thyolo, Malawi through task 
shifting and decentralization of HIV/AIDS care. Trop Med Int Health 
2010; 15: 1413–20.
10 Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, 
Grebely J. Interventions to enhance testing, linkage to care and 
treatment uptake for hepatitis C virus infection among people who 
inject drugs: a systematic review. Int J Drug Policy 2017; 47: 34–46.
11 Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis MA. 
Effectiveness of interventions to increase hepatitis C testing uptake 
among high-risk groups: a systematic review. Eur J Public Health 
2014; 24: 781–88.
12 Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review 
of hepatitis C virus treatment uptake among people who inject 
drugs in the European region. BMC Infect Dis 2014; 
14 (suppl 6): S16.
13 Mathes T, Antoine SL, Pieper D. Factors influencing adherence in 
hepatitis-C infected patients: a systematic review. BMC Infect Dis 
2014; 14: 203.
14 McDermott CL, Lockhart CM, Devine B. Outpatient directly 
observed therapy for hepatitis C among people who use drugs: 
a systematic review and meta-analysis. J Virus Erad 2018; 
4: 118–22.
15 Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV 
interventions: a qualitative meta-synthesis and systematic review of 
studies to improve linkage to care, adherence, and retention. 
EBioMedicine 2017; 17: 163–71.
16 Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of 
community based hepatitis C treatment. BMC Infect Dis 2016; 
16: 202.
17 Zhou K, Fitzpatrick T, Walsh N, et al. Interventions to optimise the 
care continuum for chronic viral hepatitis: a systematic review and 
meta-analyses. Lancet Infect Dis 2016; 16: 1409–22.
18 Downs SH, Black N. The feasibility of creating a checklist for the 
assessment of the methodological quality both of randomised and 
non-randomised studies of health care interventions. 
J Epidemiol Community Health 1998; 52: 377–84.
19 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, 
Vandenbroucke JP. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: 
guidelines for reporting observational studies. Int J Surg 2014; 
12: 1495–99.
20 Agresti A, Coull BA. Approximate is better than “exact” for interval 
estimation of binomial proportions. Am Stat 1998; 52: 119–26.
21 Higgins JPT, Green S (eds). Cochrane handbook for systematic 
reviews of interventions, version 5.0.0. London: The Cochrane 
Collaboration, 2008.
22 Begg CB, Mazumdar M. Operating characteristics of a rank 
correlation test for publication bias. Biometrics 1994; 50: 1088–101.
23 Knapp G, Hartung J. Improved tests for a random effects meta-
regression with a single covariate. Stat Med 2003; 22: 2693–710.
24 Shiha G, Metwally AM, Soliman R, Elbasiony M, Mikhail NNH, 
Easterbrook P. An educate, test, and treat programme towards 
elimination of hepatitis C infection in Egypt: a community-based 
demonstration project. Lancet Gastroenterol Hepatol 2018; 
3: 778–89.
25 Ford MM, Jordan AE, Johnson N, et al. Check Hep C: a community-
based approach to hepatitis C diagnosis and linkage to care in high-
risk populations. J Public Health Manag Pract 2018; 24: 41–48.
26 Cuadrado A, Llerena S, Cobo C, et al. Microenvironment 
eradication of hepatitis C: a novel treatment paradigm. 
Am J Gastroenterol 2018; 113: 1639–48.
27 Hashim A, O’Sullivan M, Williams H, Verma S. Developing a 
community HCV service: project ITTREAT (integrated community-
based test–stage–TREAT) service for people who inject drugs. 
Prim Health Care Res Dev 2018; 19: 110–20.
28 Lindenburg CEA, Lambers FAE, Urbanus AT, et al. Hepatitis C 
testing and treatment among active drug users in Amsterdam: 
results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 
23: 23–31.
29 Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. 
Clinical trial: a primary-care-based model for the delivery of anti-
viral treatment to injecting drug users infected with hepatitis C. 
Aliment Pharmacol Ther 2009; 29: 38–45.
30 Gilliver R, Chronister K, Lothian R, Kearley J, Read P. Daily dosing 
of direct acting antivirals from a public opioid substitution therapy 
(OST) program for marginalised clients in Kings Cross, Sydney. 
7th International Symposium on Hepatitis Care in Substance 
Users; Cascais, Portugal; Sept 19–21, 2018 (abstr A103).
31 Olaizola C, Maitre C, Bidart E, et al. Test and treat: 6 years of HCV 
rapid testing among drug users in the Bayonne area (France). 
7th International Symposium on Hepatitis Care in Substance 
Users; Cascais, Portugal; Sept 19–21, 2018 (abstr).
32 Sander-Hess C, Parker M, Maggs J, Hansford L. INTACCT: 
integrated community hepatitis C treatment. 7th International 
Symposium on Hepatitis Care in Substance Users; Cascais, 
Portugal; Sept 19–21, 2018 (abstr).
33 Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV 
treatment in lower- and middle-income countries. 
Cochrane Database Syst Rev 2013; 6: CD009987.
34 Mavegam BO, Pharr JR, Cruz P, Ezeanolue EE. Effective interventions 
to improve young adults’ linkage to HIV care in sub-Saharan Africa: 
a systematic review. AIDS Care 2017; 29: 1198–204.
35 Sharma M, Ying R, Tarr G, Barnabas R. Systematic review and 
meta-analysis of community and facility-based HIV testing to 
address linkage to care gaps in sub-Saharan Africa. Nature 2015; 
528: S77–85.
36 Fairall L, Bachmann MO, Lombard C, et al. Task shifting of 
antiretroviral treatment from doctors to primary-care nurses in 
South Africa (STRETCH): a pragmatic, parallel, cluster-randomised 
trial. Lancet 2012; 380: 889–98.
37 Seidman G, Atun R. Does task shifting yield cost savings and improve 
efficiency for health systems? A systematic review of evidence from 
low-income and middle-income countries. Hum Resour Health 2017; 
15: 29.
38 Callaghan M, Ford N, Schneider H. A systematic review of task- 
shifting for HIV treatment and care in Africa. Hum Resour Health 
2010; 8: 8.
39 Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of 
hepatitis C virus infection among people who inject drugs in the 
opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 
57 (suppl 2): S62–69.
40 Simeone C, Shapiro B, Lum PJ. Integrated HIV care is associated 
with improved engagement in treatment in an urban methadone 
clinic. Addict Sci Clin Pract 2017; 12: 19.
41 WHO. Consolidated guidelines on HIV testing services: 5Cs: 
consent, confidentiality, counselling, correct results and connection 
2015. July, 2015. https://apps.who.int/iris/handle/10665/179870 
(accessed Jan 11, 2021).
42 WHO. Consolidated guidelines on HIV prevention, diagnosis, 
treatment and care for key populations: 2016 update. July, 2016. 
https://www.who.int/hiv/pub/guidelines/keypopulations-2016/en 
(accessed Jan 11, 2021).
43 UN Office on Drugs and Crime, International Network of People 
Who Use Drugs, UNAIDS, et al. Implementing comprehensive 
HIV and HCV programmes with people who inject drugs: practical 
guidance for collaborative interventions. Vienna: United Nations 
Office on Drugs and Crime, 2017.
44 Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-based direct-acting 
antiviral therapies for HCV in people receiving opioid substitution 
therapy: an analysis of phase 3 studies. Open Forum Infect Dis 2018; 
5: ofy001.
45 Geboy AG, Nichols WL, Fernandez SJ, Desale S, Basch P, 
Fishbein DA. Leveraging the electronic health record to eliminate 
hepatitis C: screening in a large integrated healthcare system. 
PLoS One 2019; 14: e0216459.
46 Thuluvath PJ, Feldman H, Horowitz A, Lowe G. Screening for 
hepatitis C in baby boomer population using EMR pop-up and 
targeted mailing from primary care physicians in a single 
community teaching hospital. Hepatology 2016; 64 (suppl 1): 833.
47 Lambert JS, Murtagh R, Menezes D, et al. ‘HepCheck Dublin’: 
an intensified hepatitis C screening programme in a homeless 
population demonstrates the need for alternative models of care. 
BMC Infect Dis 2019; 19: 128.
48 Remy AJ, Bouchkira H, Lamarre P, Montabone S. Hepatitis 
Mobile Team: a new concept for benefit toward drugs users and 
precarious people with hepatitis C in France. Hepatology 2016; 
64 (suppl 1): 775.
Articles
www.thelancet.com/lancetgh   Vol 9   April 2021 e445
49 Surey J, Story A, Menezes D, Conneely J, Hayward A. EARTH 
Study (phase 1): expanding access to rapid treatment for hepatitis C. 
J Hepatol 2016; 64 (suppl): S461–62.
50 David C, David D, Essex W, Deming P, Qualls CR, Mera J. Hepatitis 
C treatment outcomes in a pharmacist-managed clinic in a rural 
tribal health system. Hepatology 2017; 66 (suppl 1): 609.
51 Radley A, Tait J, Stephens B, Dillon J. Can dried blood spot testing 
for hepatitis C in community pharmacy increase uptake? Interim 
reporting of a quasi-experimental study. 4th International Conference 
on Hepatitis in Substance Users; Sydney, NSW, Australia; 
Oct 7–9, 2015 (abstr).
52 Beste LA, Glorioso TJ, Ho PM, et al. Telemedicine specialty support 
promotes hepatitis C treatment by primary care providers in the 
Department of Veterans Affairs. Am J Med 2017; 130: 432–38.e3.
53 Chan PP, Mohsen W, Whelan MC, et al. Project ECHO in Australia: 
a novel tele-mentoring service to aid hepatitis C treatment in 
difficult to access populations. Hepatology 2017; 66 (suppl 1): 581.
54 Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, 
Grebely J. Direct-acting antiviral treatment for hepatitis C among 
people who use or inject drugs: a systematic review and 
meta-analysis. Lancet Gastroenterol Hepatol 2018; 3: 754–67.
